The FDA has issued a warning regarding Abbott's FreeStyle Libre 3 glucose monitor sensors due to potential inaccuracies that could lead to serious health risks. This warning follows reports linking these devices to 736 serious injuries and seven fatalities. Despite these challenges, Abbott Laboratories maintains a robust financial profile and global market presence, characterized by strong profitability and efficient operations.

雅培

<p>美国食品药品监督管理局（FDA）已对雅培的 FreeStyle Libre 3 血糖监测传感器发出警告，原因是可能存在不准确性，这可能导致严重的健康风险。此警告是在报告将这些设备与 736 起严重伤害和七起死亡事件联系起来之后发布的。尽管面临这些挑战，雅培仍保持强健的财务状况和全球市场存在，表现出强大的盈利能力和高效的运营</p>

美国食品药品监督管理局（FDA）对雅培（ABT）葡萄糖监测仪发出警告，此前有报告称该设备与死亡事件有关